Compare AbbVie Inc (ABBV) vs Paycom Software Inc (PAYC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Paycom Software Inc — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while Paycom Software Inc trades at $138.33 (market cap $6.70B). The key difference: AbbVie Inc is far larger — about 67.2× Paycom Software Inc's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | PAYC | |
|---|---|---|
Market Cap | $449.91B | $6.70B |
Sector | Health | Technology |
52-Week High | $261.07 | $238.80 |
52-Week Low | $184.85 | $113.59 |
Enterprise Value | $513.38B | $7.31B |
Dividend Yield | 2.72% | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
Paycom Software (PAYC) trades at $143.78, up 3.28% on the day, with a bullish technical signal and strong fundamentals including a 22.44% net income margin and 37.15% ROE. Recent earnings beat expectations in Q1 2026, and the company maintains robust cash flow from operations of $678.9 million in 2025. Analyst consensus is mixed with a $151 price target, while recent news highlights its value stock appeal and industry awards.
The outlook for PAYC is positive with solid revenue growth and profitability, though risks include competitive pressures and market volatility. The stock's current valuation metrics, such as a P/E of 16.19, suggest room for upside if earnings momentum continues, but investors should weigh execution risks against the bullish analyst sentiment and institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →
